Refine by
Plasma Protein Articles & Analysis
16 news found
Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries. Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, ...
Ongoing and planned studies with both AstraZeneca and the University of Nebraska Medical Center will utilize standardized plasma protein profiling workflows, including Thermo Fisher's newly developed ultra-high throughput plasma protein profiling (uHTPPP) workflow, for biomarker discovery, for a range of conditions. ...
GC Pharma is a pioneer in vaccines and protein therapeutics and has long been dedicated to research and development of hemophilia treatments, currently developing its non-factor therapy for hemophilia A. ...
In addition to the clinical development of specific plasma fractions and protein inhibitors, Alkahest is focused on developing a complete understanding of the human plasma proteome. This unique proteomic platform of targets will help Grifols and Alkahest to unlock new therapeutics and diagnostics, develop new plasma ...
By reducing the amount of B2M in the plasma, we hope to introduce an effective way to lessen this impairment and allow patients on hemodialysis for ESRD to achieve improved treatment outcomes and quality of ...
Norris, Ph.D., and colleagues at The Rockefeller University in New York City (up to $320,000 award) are developing a blood test that detects changes in a protein called high molecular weight kininogen — a biomarker that identifies patients with vascular and inflammatory abnormalities that can contribute to the pathology of Alzheimer’s. ...
In recent years, Grifols expanded and diversified its access to plasma and sustained its leadership position through a network of 300 plasma donation centers in the United States throughout more than 30 federal states and Germany in several Bundesländer. Over the last years, Grifols has been building up plasma and medicinal products ...
The gross margin was 45.9% (45.7% in 2018), driven by solid demand of the main plasma proteins, enhanced production efficiencies and a stable the cost of plasma. ...
AboutAKST4290 AKST4290 is an orally administered CCR3 inhibitor that blocks the action of eotaxin, an immunomodulatory protein that increases as humans age and with specific age-related diseases. ...
About AKST4290 AKST4290 is an orally administered CCR3 inhibitor that blocks the action of eotaxin, an immunomodulatory protein that increases as humans age and with specific age-related diseases. ...
About AKST4290 AKST4290 is an orally administered CCR3 inhibitor that blocks the action of eotaxin, an immunomodulatory protein that increases as humans age and with specific age-related diseases. ...
GRF6019 and GRF6021, proprietary plasma fractions, are developed and provided by Grifols. In animal models, these plasma fractions enhance neurogenesis, improve age-related deficits in learning and memory, and reduce neuroinflammation. ...
The Company will present data from recent studies demonstrating the rationale for study of its plasma fraction therapies for certain neurological and age-related diseases. ...
Through their joint commitment, Thermo Fisher and Cedars-Sinai aim to develop a pathway to a future that includes precision medicine by: Developing robust data acquisition strategies for global plasma protein profiling and peptide selective reaction monitoring (SRM) assays for the direct analysis of plasma with or without enrichment. ...
GRF6019 and GRF6021, proprietary plasma fractions, are developed and provided by Grifols. In animal models, GRF6019 ...
CSL Behring, a global leader in the plasma protein biotherapies industry and a subsidiary of CSL Limited (ASX:CSL), has awarded advocacy grants totaling almost $100,000 to six patient organizations through the Local Empowerment for Advocacy Development (LEAD) program. ...